Loss of Argininosuccinate Synthetase-1 (ASS1) Occurs in Esophageal Adenocarcinoma and Represents a Promising Biomarker for Therapy with Pegargiminase.

Cancers (Basel) · 2025 · PMC12650347 · PMID 41300990

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

barely not statistically significantp = 0.063so close (0.05 < p ≤ 0.1)

Furthermore, the frequency of ASS1 loss or low ASS1 expression was higher in patients following neoadjuvant therapy ( p = 0.063; barely not statistically significant).

also in 13 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.